Systemic treatment of advanced biliary tract Carcinoma

Emerging roles of targeted therapy and molecular profiling

Edward Wyluda, Nelson Shu-Sang Yee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Biliary tract carcinoma (BTC) represents a heterogeneous group of tumors, and the overall prognosis is poor. Limited progress has been made in systemic therapy of this disease. Recent advances have been made in understanding the molecular biology of biliary tract tumor, development of targeted therapeutics, and molecular profiling of tumors. Methods: The currently used systemic chemotherapy and emerging therapeutic regimens in BTC are reviewed. An overview of the signaling pathways in biliary tract neoplasia and the sites for targeted agents is provided. The pre-clinical and clinical data obtained from the literature in PubMed as well as the ongoing clinical studies as displayed in www.ClinicalTrials.gov are discussed. The potential utility of molecular profiling of tumors as an approach to personalize treatment for patients with BTC is explored. Results: The combination of gemcitabine and cisplatin produced significant though limited benefit in prolonging survival. This regimen has become the standard of care for advanced BTC as well as the backbone for further development of systemic therapy. The genetic alterations involved in BTC have been explored as targets for the development of therapeutic agents. Combination of targeted therapeutics with cytotoxic chemotherapy potentially improves the treatment response in patients with BTC. Multiplatform analysis of biliary tract tumors provides new opportunity for personalizing treatment of individual patients. Conclusion: Therapeutic regimens are evolving with the hope of improving the clinical outcomes for patients with BTC. Future strategies by integration of targeted therapeutics and molecular profiling are expected to help accomplish the goal of precision therapy in BTC.

Original languageEnglish (US)
Pages (from-to)80-86
Number of pages7
JournalClinical Cancer Drugs
Volume2
Issue number2
StatePublished - Dec 1 2015

Fingerprint

Molecular Targeted Therapy
Biliary Tract
Carcinoma
Therapeutics
Neoplasms
gemcitabine
Drug Therapy
Standard of Care
PubMed
Cisplatin
Molecular Biology

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Cancer Research

Cite this

@article{e26e78077f2d472e8adbcffb3c6ab424,
title = "Systemic treatment of advanced biliary tract Carcinoma: Emerging roles of targeted therapy and molecular profiling",
abstract = "Background: Biliary tract carcinoma (BTC) represents a heterogeneous group of tumors, and the overall prognosis is poor. Limited progress has been made in systemic therapy of this disease. Recent advances have been made in understanding the molecular biology of biliary tract tumor, development of targeted therapeutics, and molecular profiling of tumors. Methods: The currently used systemic chemotherapy and emerging therapeutic regimens in BTC are reviewed. An overview of the signaling pathways in biliary tract neoplasia and the sites for targeted agents is provided. The pre-clinical and clinical data obtained from the literature in PubMed as well as the ongoing clinical studies as displayed in www.ClinicalTrials.gov are discussed. The potential utility of molecular profiling of tumors as an approach to personalize treatment for patients with BTC is explored. Results: The combination of gemcitabine and cisplatin produced significant though limited benefit in prolonging survival. This regimen has become the standard of care for advanced BTC as well as the backbone for further development of systemic therapy. The genetic alterations involved in BTC have been explored as targets for the development of therapeutic agents. Combination of targeted therapeutics with cytotoxic chemotherapy potentially improves the treatment response in patients with BTC. Multiplatform analysis of biliary tract tumors provides new opportunity for personalizing treatment of individual patients. Conclusion: Therapeutic regimens are evolving with the hope of improving the clinical outcomes for patients with BTC. Future strategies by integration of targeted therapeutics and molecular profiling are expected to help accomplish the goal of precision therapy in BTC.",
author = "Edward Wyluda and Yee, {Nelson Shu-Sang}",
year = "2015",
month = "12",
day = "1",
language = "English (US)",
volume = "2",
pages = "80--86",
journal = "Clinical Cancer Drugs",
issn = "2212-697X",
publisher = "Bentham Science Publishers",
number = "2",

}

Systemic treatment of advanced biliary tract Carcinoma : Emerging roles of targeted therapy and molecular profiling. / Wyluda, Edward; Yee, Nelson Shu-Sang.

In: Clinical Cancer Drugs, Vol. 2, No. 2, 01.12.2015, p. 80-86.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Systemic treatment of advanced biliary tract Carcinoma

T2 - Emerging roles of targeted therapy and molecular profiling

AU - Wyluda, Edward

AU - Yee, Nelson Shu-Sang

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: Biliary tract carcinoma (BTC) represents a heterogeneous group of tumors, and the overall prognosis is poor. Limited progress has been made in systemic therapy of this disease. Recent advances have been made in understanding the molecular biology of biliary tract tumor, development of targeted therapeutics, and molecular profiling of tumors. Methods: The currently used systemic chemotherapy and emerging therapeutic regimens in BTC are reviewed. An overview of the signaling pathways in biliary tract neoplasia and the sites for targeted agents is provided. The pre-clinical and clinical data obtained from the literature in PubMed as well as the ongoing clinical studies as displayed in www.ClinicalTrials.gov are discussed. The potential utility of molecular profiling of tumors as an approach to personalize treatment for patients with BTC is explored. Results: The combination of gemcitabine and cisplatin produced significant though limited benefit in prolonging survival. This regimen has become the standard of care for advanced BTC as well as the backbone for further development of systemic therapy. The genetic alterations involved in BTC have been explored as targets for the development of therapeutic agents. Combination of targeted therapeutics with cytotoxic chemotherapy potentially improves the treatment response in patients with BTC. Multiplatform analysis of biliary tract tumors provides new opportunity for personalizing treatment of individual patients. Conclusion: Therapeutic regimens are evolving with the hope of improving the clinical outcomes for patients with BTC. Future strategies by integration of targeted therapeutics and molecular profiling are expected to help accomplish the goal of precision therapy in BTC.

AB - Background: Biliary tract carcinoma (BTC) represents a heterogeneous group of tumors, and the overall prognosis is poor. Limited progress has been made in systemic therapy of this disease. Recent advances have been made in understanding the molecular biology of biliary tract tumor, development of targeted therapeutics, and molecular profiling of tumors. Methods: The currently used systemic chemotherapy and emerging therapeutic regimens in BTC are reviewed. An overview of the signaling pathways in biliary tract neoplasia and the sites for targeted agents is provided. The pre-clinical and clinical data obtained from the literature in PubMed as well as the ongoing clinical studies as displayed in www.ClinicalTrials.gov are discussed. The potential utility of molecular profiling of tumors as an approach to personalize treatment for patients with BTC is explored. Results: The combination of gemcitabine and cisplatin produced significant though limited benefit in prolonging survival. This regimen has become the standard of care for advanced BTC as well as the backbone for further development of systemic therapy. The genetic alterations involved in BTC have been explored as targets for the development of therapeutic agents. Combination of targeted therapeutics with cytotoxic chemotherapy potentially improves the treatment response in patients with BTC. Multiplatform analysis of biliary tract tumors provides new opportunity for personalizing treatment of individual patients. Conclusion: Therapeutic regimens are evolving with the hope of improving the clinical outcomes for patients with BTC. Future strategies by integration of targeted therapeutics and molecular profiling are expected to help accomplish the goal of precision therapy in BTC.

UR - http://www.scopus.com/inward/record.url?scp=85042573748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042573748&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 80

EP - 86

JO - Clinical Cancer Drugs

JF - Clinical Cancer Drugs

SN - 2212-697X

IS - 2

ER -